Easing the burden: Characterizing the disease burden of neonatal group B streptococcal disease to motivate prevention

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1209-1211

  Schrag, Stephanie J ^a   Schuchet, Anne ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL VACCINE; CHLORHEXIDINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; HUMAN; INFECTION PREVENTION; LABOR; NEWBORN MORBIDITY; NEWBORN MORTALITY; NOTE; PENICILLIN RESISTANCE; PREMATURE LABOR; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; COST OF ILLNESS; DISEASE TRANSMISSION; ECONOMICS; FEMALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION;

COST OF ILLNESS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 2342573536     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382889     Document Type: Note

References (18)

1. Weisner AM, Johnson AP, Lamagni TL, et al. Characterization of group B streptococci from infants with invasive disease in England and Wales. Clin Infect Dis 2004; 38:1203-8 (in this issue).
2. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342:15-20.
3. Davies HD, Adair CE, Ma D, Sauve R, Schuchat A. Prospective population-based rates of early-onset GBS disease in two Canadian regions: impact of prevention guidelines [abstract 1733]. In: Program and abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:684.
4. Andreu A, Sanfeliu I, Vinas L, et al. Decreasing incidence of perinatal group B streptococcal disease (Barcelona 1994-2002): relation with hospital prevention policies. Enferm Infecc Microbiol Clin 2003; 21:174-9.
5. Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatr Infect Dis J 1999; 18:524-8.
6. Lyytikainen O, Nuorti JP, Halmesmaki E, et al. Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis 2003; 9:469-73.
7. Dahl MS, Tessin I, Trollfors B. Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis. Int J Infect Dis 2003; 7:113-9.
8. Thinkhamrop J, Limpongsanurak S, Festin MR, et al. Infections in international pregnancy study: performance of the optical immunoassay test for detection of group B Streptococcus. J Clin Microbiol 2003; 41:5288-90.
9. Madhi S, Radebe K, Crewe-Brown H, et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 2003; 23:15-23.
10. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002; 347:233-9.
11. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003; 3:201-13.
12. Facchinetti F, Piccinini F, Mordini B, Volpe A. Chlorhexidine vaginal flushings versus systemic ampicillin in the prevention of vertical transmission of neonatal group B Streptococcus, at term. J Matern Fetal Neonatal Med 2002; 11:84-8.
13. Stray-Pedersen B, Bergan T, Hafstad A, Normann E, Grogaard J, Vangdal M. Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents 1999; 12:245-51.
14. Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity in Malawi: clinical trial. BMJ 1997; 315:216-9 (discussion: 220).
15. Schrag SJ, Whitney C, Schuchat A. Neonatal group B streptococcal disease: how infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol 2000; 21:473-83.
16. Baker C, Rench M, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-72.
17. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: a tool for decision making. Washington, DC: National Academy Press, 2001.
18. Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003; 21:3442-5.